Subsequent Events	6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On July 1, 2026, XeCare LLC and Apostrophe Pharmacy LLC, each a wholly-owned subsidiary of the Company (each a “RPA Seller” and, collectively, the “RPA Sellers”), entered into a Master Receivables Purchase Agreement (the “Receivables Purchase Agreement”) with JPMorgan Chase Bank, N.A., as purchaser (the “Purchaser”). The Receivables Purchase Agreement provides for an uncommitted facility with an initial aggregate limit of $400.0 million (the “Program Limit”). Pursuant to the Receivables Purchase Agreement, each RPA Seller may, subject to the terms and conditions therein, offer to sell certain of its eligible receivables for cash to the Purchaser (“Purchased Receivables”) at a discount. Limited recourse is available to the Purchaser pursuant to certain indemnity and repurchase obligations described in the Receivables Purchase Agreement in connection with certain representations, warranties and covenants to the Purchaser regarding the Purchased Receivables. No such representation, warranty, or covenant gives the Purchaser recourse against the RPA Sellers in response to credit loss experienced by Purchaser due to any debtor of a Purchased Receivable being insolvent, declining in creditworthiness, or having an inability to pay. In connection with the Receivables Purchase Agreement, pursuant to a Performance Undertaking in favor of the Purchaser, dated July 1, 2026, the Company agreed to guarantee the performance of the RPA Sellers of their obligations under the Receivables Purchase Agreement. In July 2026, the Company entered into a one-time agreement with a company in the peptide manufacturing industry to obtain the expertise and technology necessary for the Company to independently manufacture certain peptide active pharmaceutical ingredients in exchange for aggregate cash payments of up to $30.0 million, contingent upon the achievement of certain milestones, and expected to be paid over the next 12 months.

On July 1, 2026, XeCare LLC and Apostrophe Pharmacy LLC, each a wholly-owned subsidiary of the Company (each a “RPA Seller” and, collectively, the “RPA Sellers”), entered into a Master Receivables Purchase Agreement (the “Receivables Purchase Agreement”) with JPMorgan Chase Bank, N.A., as purchaser (the “Purchaser”). The Receivables Purchase Agreement provides for an uncommitted facility with an initial aggregate limit of $400.0 million (the “Program Limit”). Pursuant to the Receivables Purchase Agreement, each RPA Seller may, subject to the terms and conditions therein, offer to sell certain of its eligible receivables for cash to the Purchaser (“Purchased Receivables”) at a discount. Limited recourse is available to the Purchaser pursuant to certain indemnity and repurchase obligations described in the Receivables Purchase Agreement in connection with certain representations, warranties and covenants to the Purchaser regarding the Purchased Receivables. No such representation, warranty, or covenant gives the Purchaser recourse against the RPA Sellers in response to credit loss experienced by Purchaser due to any debtor of a Purchased Receivable being insolvent, declining in creditworthiness, or having an inability to pay. In connection with the Receivables Purchase Agreement, pursuant to a Performance Undertaking in favor of the Purchaser, dated July 1, 2026, the Company agreed to guarantee the performance of the RPA Sellers of their obligations under the Receivables Purchase Agreement.

In July 2026, the Company entered into a one-time agreement with a company in the peptide manufacturing industry to obtain the expertise and technology necessary for the Company to independently manufacture certain peptide active pharmaceutical ingredients in exchange for aggregate cash payments of up to $30.0 million, contingent upon the achievement of certain milestones, and expected to be paid over the next 12 months.